Press Release

Myovant Sciences to Present at Upcoming Investor Conferences

27 Feb 2017 at 12:00 pm ET

PDF Version

BASEL, Switzerland, Feb. 27, 2017 /PRNewswire/ — Myovant Sciences (NYSE: MYOV), a leading clinical-stage biopharmaceutical company focused on women’s health and other endocrine-related disorders, today announced upcoming presentations at two investor conferences:

  • March 7 at 10:40 a.m. ET at the Cowen and Company 37th Annual Healthcare Conference
  • March 14 at 2:35 p.m. ET at the Barclays Global Healthcare Conference


A simultaneous webcast will be available for each conference via the Events page under the Investors and Media section of Myovant’s website at Please connect to the company’s website at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to listen to the webcast. A replay will also be available at the same location for 30 days following each conference.

About Myovant Sciences

Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women’s health and other endocrine-related disorders. Myovant’s lead product candidate is relugolix, an oral, once-daily small molecule that acts as a GnRH receptor antagonist. Myovant plans to conduct five international Phase 3 clinical trials of relugolix and recently initiated one of two international trials comprising its Phase 3 program in women with heavy menstrual bleeding associated with uterine fibroids. Two additional Phase 3 trials are planned in women with endometriosis-associated pain, as well as one in men with advanced prostate cancer. Myovant is simultaneously developing MVT-602, an analog of kisspeptin, for the treatment of female infertility as part of assisted reproduction. Over time, the company intends to expand its development pipeline to include other potential treatments for women’s health and endocrine-related disorders. For more information, please visit the company’s website at

To view the original version on PR Newswire, visit:

SOURCE Myovant Sciences